Bafna Pharmaceuticals Ltd vs Shree Ganesh Biotech India Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 18, 2026

Key Highlights

The Latest Trading Price of Bafna Pharmaceuticals Ltd is ₹ 137 as of 18 May 15:30 . The P/E Ratio of Bafna Pharmaceuticals Ltd changed from 55.8 on March 2021 to 42.6 on March 2025 . This represents a CAGR of -5.26% over 5 yearsThe P/E Ratio of Shree Ganesh Biotech India Ltd changed from 740.6 on March 2021 to 90 on March 2025 . This represents a CAGR of -34.40% over 5 years The Market Cap of Bafna Pharmaceuticals Ltd changed from ₹ 324.8 crore on March 2021 to ₹ 177.42 crore on March 2025 . This represents a CAGR of -11.39% over 5 yearsThe Market Cap of Shree Ganesh Biotech India Ltd changed from ₹ 236.18 crore on March 2021 to ₹ 35.88 crore on March 2025 . This represents a CAGR of -31.40% over 5 years The revenue of Bafna Pharmaceuticals Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 39.51 crore. This represent the decline of -100% The revenue of Shree Ganesh Biotech India Ltd for the Mar '26 is ₹ 2.4 crore as compare to the Dec '25 revenue of ₹ 1.07 crore. This represent the growth of 124.3% The ebitda of Bafna Pharmaceuticals Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 4.27 crore. This represent the decline of -100% The ebitda of Shree Ganesh Biotech India Ltd for the Mar '26 is ₹ -0.15 crore as compare to the Dec '25 ebitda of ₹ 0.32 crore. This represent the decline of -146% The net profit of Bafna Pharmaceuticals Ltd changed from ₹ -0.72 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00% The net profit of Shree Ganesh Biotech India Ltd changed from ₹ 0.24 crore to ₹ -0.15 crore over 8 quarters. This represents a CAGR of NaN% The Dividend Payout of Bafna Pharmaceuticals Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Shree Ganesh Biotech India Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Bafna Pharmaceuticals Ltd

Bafna Pharmaceuticals Limited (BPL) was started as a proprietary concern in 1981 by Mr. Bafna Mahaveer Chand in the name of Bafna Pharmaceutical and is engaged in the manufacturing of pharmaceutical formulations of Betalactum and Non Betalactum products.
The first manufacturing unit was set up at Madhavaram (Chennai) during October 1984 for manufacture of tablets with an installed capacity of 420 lacs tablets p.a.
Subsequently the capsule line was added during 1987 with a capacity of 300 lacs capsule p.a. and then liquid line with an installed capacity of 45000 lts p.a was added in 1990. Bafna Pharmaceuticals, incorporated in 1995, had acquired the entire business of the proprietary concern.
During the year 2001, the company constructed a separate block at Madhavaram for manufacturing Betalactum products.

About Shree Ganesh Biotech India Ltd

Shree Ganesh Biotech India Limited was incorporated on September 2, 1982, as 'S.P. Commercial Co. Limited' with the Registrar of Companies, West Bengal.
The Company got the Certificate of Commencement of Business on September 14, 1982.
The Company was incorporated with an object to carry on the business of builders, Contractors and to deal in property and also to do investment and finance business. In 2010, pursuant to a Scheme of Amalgamation, Shree Ganesh Bio-Tech (India) Private Limited was merged with S.P. Commercial Co. Limited pursuant to the order of the Hon'ble High at Calcutta dated February 15, 2010.
The entire business of Shree Ganesh Bio-Tech (India) Private Limited consisting of trading and distribution of seeds were transferred to S.P. Commercial Co. Limited.
Subsequently, Shree Ganesh Bio-Tech (India) Private Limited was dissolved pursuant to the said Scheme of Amalgamation and the name of the Company was changed to Shree Ganesh Bio-Tech (India) Limited.

FAQs for the comparison of Bafna Pharmaceuticals Ltd and Shree Ganesh Biotech India Ltd

Which company has a larger market capitalization, Bafna Pharmaceuticals Ltd or Shree Ganesh Biotech India Ltd?

Market cap of Bafna Pharmaceuticals Ltd is 326 Cr while Market cap of Shree Ganesh Biotech India Ltd is 24 Cr

What are the key factors driving the stock performance of Bafna Pharmaceuticals Ltd and Shree Ganesh Biotech India Ltd?

The stock performance of Bafna Pharmaceuticals Ltd and Shree Ganesh Biotech India Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Bafna Pharmaceuticals Ltd and Shree Ganesh Biotech India Ltd?

As of May 18, 2026, the Bafna Pharmaceuticals Ltd stock price is INR ₹138.0. On the other hand, Shree Ganesh Biotech India Ltd stock price is INR ₹0.62.

How do dividend payouts of Bafna Pharmaceuticals Ltd and Shree Ganesh Biotech India Ltd compare?

To compare the dividend payouts of Bafna Pharmaceuticals Ltd and Shree Ganesh Biotech India Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.